COVID Testing Conundrum Feeds FDA Resource, Reform Debates

article image

The pandemic experience will be a major factor in upcoming user fee talks and in a diagnostics regulatory reform debate that continues to escalate.

The COVID-19 pandemic is all at once presenting a massive challenge to FDA’s workload capacity in the diagnostics space and placing a big spotlight on the instabilities in the US diagnostics oversight framework. As a result, FDA’s ever-evolving approach to the COVID-19 testing challenge will be a key driver in several upcoming Washington, DC, debates in the medtech sector, particularly around agency resources and diagnostics regulatory reform.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: